Shopping Cart
- Remove All
Your shopping cart is currently empty
BTX161
😃Good
Catalog No. T60478Cas No. 2052301-24-1
BTX161 is a Thalidomide analogue. BTX161 is a potent CKIα degrader. In human AML cells, BTX161 mediates the CKIα degradation better than Lenalidomide as well as activates DNA damage response (DDR) and p53, and also stabilizes the p53 antagonist MDM2[1].
BTX161
😃Good
Catalog No. T60478Cas No. 2052301-24-1
BTX161 is a Thalidomide analogue. BTX161 is a potent CKIα degrader. In human AML cells, BTX161 mediates the CKIα degradation better than Lenalidomide as well as activates DNA damage response (DDR) and p53, and also stabilizes the p53 antagonist MDM2[1].
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $1,140 | 6-8 weeks | |
| 50 mg | $1,490 | 6-8 weeks | |
| 100 mg | $2,360 | 6-8 weeks |
Bulk & Custom
Add to Cart
Questions
View MoreContact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | BTX161 is a Thalidomide analogue. BTX161 is a potent CKIα degrader. In human AML cells, BTX161 mediates the CKIα degradation better than Lenalidomide as well as activates DNA damage response (DDR) and p53, and also stabilizes the p53 antagonist MDM2[1]. |
| In vitro | BTX161 (25 μM; 4 hours; MV4-11 cells) enhances the expression of Wnt targets such as MYC without altering MDM2 mRNA levels [1]. At a concentration of 10 μM over 6 hours in MV4-11 cells, BTX161 independently increases p53 and MDM2 protein levels. When combined with THZ1, and especially with both THZ1 and CDK9, it further elevates p53 expression and maximizes caspase 3 activation [1]. |
| Molecular Weight | 272.3 |
| Formula | C15H16N2O3 |
| Cas No. | 2052301-24-1 |
Storage & Solubility Information
| Storage | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy BTX161 | purchase BTX161 | BTX161 cost | order BTX161 | BTX161 chemical structure | BTX161 in vitro | BTX161 formula | BTX161 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.